title: Use of melanotan I and II in the general population.
authors.forename: Michael
authors.initials: M
authors.lastname: Evans-Brown
authors.forename: Rob T
authors.initials: RT
authors.lastname: Dawson
authors.forename: Martin
authors.initials: M
authors.lastname: Chandler
authors.forename: Jim
authors.initials: J
authors.lastname: McVeigh
mesh_terms: D006801:Humans; D008297:Male; D004366:Nonprescription Drugs / Q000008:administration & dosage / Q000009:adverse effects; D010410:Penile Erection / Q000187:drug effects; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000009:adverse effects; D019966:Substance-Related Disorders / Q000209:etiology*; D055107:Suntan / Q000187:drug effects*; D000521:alpha-MSH / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D004366:Nonprescription Drugs; D010456:Peptides, Cyclic; C079282:melanotan-II; D000521:alpha-MSH; C027756:MSH, 4-Nle-7-Phe-alpha-